DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pjc2wt/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering.
Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly.
It is expected that the prevalence of Parkinson's disease in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Brazil will increase from 3.2m people in 2012 to 4.3m people in 2022, driven by an aging population in all markets. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. The publisher expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Key Questions Answered
- According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?
- With the recent launch of Xadago and Rytary and an additional four drugs in the late-stage pipeline, which products are forecast to generate the highest sales over 2012-2022?
- What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
- An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
- What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Opportunity and Unmet Need
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
11 Appendix
Companies Mentioned
- Merck
- Roche
- AbbVie
- UCB
- GlaxoSmithKline
- Novartis
- Orion
- Newron
- Impax
- Lundbeck
For more information visit http://www.researchandmarkets.com/research/pjc2wt/pharmapoint
